In the Lamictal case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of SmithKline Beacham’s Lamictal, prescription drugs used to treat epilepsy, bipolar disorder and other medical conditions. The class also includes direct purchasers of generic versions of Lamictal from Teva, SmithKline’s co-defendant and alleged co-conspirator. The complaint alleges that SmithKline entered a reverse payment patent settlement with Teva to delay launching its first filed generic to compete with SmithKline’s $2 billion a year Lamictal Tablets. Such an agreement violates §§ 1 and 2 of the Sherman Act.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 11/12/2015
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Joseph T. Lukens email@example.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771